abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation
June 21, 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, June 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
June 16, 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, June 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
Logo.png
Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 Conference
May 31, 2022 10:42 ET | Biofrontera Inc.
WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners
May 25, 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
Logo.png
New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera’s Ameluz®
May 24, 2022 11:29 ET | Biofrontera Inc.
WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin...
Logo.png
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
May 19, 2022 09:48 ET | Biofrontera Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the...
logo.png
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ
May 19, 2022 09:15 ET | Adhera Therapeutics, Inc.
Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the...
Logo 1.png
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 08:00 ET | Aeterna Zentaris Inc
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Logo.png
Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement
May 16, 2022 08:00 ET | Biofrontera Inc.
WOBURN, MA., May 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Engages the FreeMind Group to Support Grant Funding
May 13, 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, May 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...